Population Health Sciences

You are here

Home > Publications > Publications

Publications

Found 134 results
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is D  [Clear All Filters]
Journal Article
Hajifathalian K, Kumar S, Newberry C, Shah S, Fortune B, Krisko T, Ortiz-Pujols S, Zhou XKathy, Dannenberg AJ, Kumar R et al..  2020.  Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City.. Obesity (Silver Spring).
Greenlee H, Shi Z, Hibshoosh H, Giri DD, Ahmed A, Williams S, Falcone DJ, Winston LA, Zhou XK, Hudis CA et al..  2019.  Obesity-associated Breast Inflammation among Hispanic/Latina Breast Cancer Patients.. Cancer Prev Res (Phila). 12(1):21-30.
Doraiswamy S, Cheema S, Mamtani R.  2020.  Older people and epidemics: a call for empathy.. Age Ageing. 49(3):493.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..  2019.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, Ridling LA, Dittus C, Chen Z, Huang X et al..  2019.  A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.. Blood. 133(11):1201-1204.
Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, Huang X, DiLiberto M, Chen-Kiang S, Leonard JP.  2019.  A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.. Leuk Lymphoma. :1-5.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
Beltran H, Oromendia C, Danila DC, Montgomery B, Hoimes C, Szmulewitz RZ, Vaishampayan U, Armstrong AJ, Stein M, Pinski J et al..  2019.  A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.. Clin Cancer Res. 25(1):43-51.
DeLia D, Tong J, Gaboda D, Casalino LP.  2014.  Post-discharge follow-up visits and hospital utilization by Medicare patients, 2007-2010.. Medicare Medicaid Res Rev. 4(2)
Das LT, Abramson EL, Stone AE, Kondrich JE, Kern LM, Grinspan ZM.  2017.  Predicting frequent emergency department visits among children with asthma using EHR data.. Pediatr Pulmonol. 52(7):880-890.
McDonough TL, Paolicchi JM, Heier LA, Das N, Engel M, Perlman JM, Grinspan ZM.  2017.  Prediction of Future Epilepsy in Neonates With Hypoxic-Ischemic Encephalopathy Who Received Selective Head Cooling.. J Child Neurol. 32(7):630-637.
Lazow SP, Venn RA, Lubor B, Kocharian G, Kreines FM, Gilbert E, Marnell CS, Cricco-Lizza E, Cooley V, Christos P et al..  2019.  The PreOp Program: Intensive Preclinical Surgical Exposure is Associated With Increased Medical Student Surgical Interest and Competency.. J Surg Educ.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-Muhannadi H, Petropoulos IN, Khan A, Ashawesh KAE, Dukhan KMO et al..  2020.  Prevalence and management of diabetic neuropathy in secondary care in Qatar.. Diabetes Metab Res Rev. 36(4):e3286.
Christos PJ, Chemaitelly H, Abu-Raddad LJ, Zirie MAli, Deleu D, Mushlin AI.  2014.  Prevention of type II diabetes mellitus in Qatar: Who is at risk? Qatar Med J. 2014(2):70-81.
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Shoag J, Liu D, Ma X, Oromendia C, Christos P, Ballman K, Angulo C, Cai PY, Gaffney C, Klein E et al..  2020.  Prognostic value of the SPOP mutant genomic subclass in prostate cancer.. Urol Oncol.
Hood JE, Behrends CN, Irwin A, Schackman BR, Chan D, Hartfield K, Hess J, Banta-Green C, Whiteside L, Finegood B et al..  2019.  The projected costs and benefits of a supervised injection facility in Seattle, WA, USA.. Int J Drug Policy. 67:9-18.
Subbaramaiah K, Iyengar NM, Morrow M, Elemento O, Zhou XKathy, Dannenberg AJ.  2019.  Prostaglandin E down-regulates sirtuin 1 (SIRT1), leading to elevated levels of aromatase, providing insights into the obesity-breast cancer connection.. J Biol Chem. 294(1):361-371.
Xie Y, Valdimarsdóttir UA, Wang C, Zhong XR, Gou Q, Zheng H, Deng L, He P, Hu K, Fall K et al..  2020.  Public health insurance and cancer-specific mortality risk among patients with breast cancer: A prospective cohort study in China.. Int J Cancer.
Barfield E, Deshmukh F, Slighton E, Lentine J, Lu Y, Ma X, Christos PJ, Sockolow RE, Loughlin G, Pillai S.  2020.  Pulmonary Manifestations in Adolescents With Inflammatory Bowel Disease.. Clin Pediatr (Phila). :9922820910821.
Bishop TF, Ryan AM, Chen MA, Mendelsohn J, Gottlieb D, Shih S, Desai P, Wolff EA, Casalino LP.  2016.  A Randomized, Controlled Trial of a Shared Panel Management Program for Small Practices.. Health Serv Res. 51(5):1796-813.